Fresenius Medical Care AG : The technical configuration is positive
Entry price | Target | Stop-loss | Potential |
---|
€85.64 |
€90 |
€83.2 |
+5.09% |
---|
The underlying tendency is to the upside for shares in Fresenius Medical Care and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated.
Summary● The company has solid fundamentals for a short-term investment strategy.
Strengths● The group's high margin levels account for strong profits.
● For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
● Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses● According to forecast, a sluggish sales growth is expected for the next fiscal years.
● The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
● For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.